The increased expression of SNHG12 also correlated with shorter survival time of patients, suggesting that it may be utilized as a potential biomarker for the improved prognosis, and as a target for the treatment of bladder cancer. This evidence concerns the gene SNHG12 and urinary bladder carcinoma.